Transient Cell Line Construction Services
Inquiry
As a preclinical CRO specializing in oncology, Alfa Cytology offers transient cell line construction services designed to achieve rapid and efficient gene expression validation and protein production through the temporary expression of exogenous genes in host cells. These services provide flexible and cost-effective solutions for the early stages of your oncology research programs.
Introduction to Transient Cell Line
Transient cell lines are cellular models in which exogenous gene expression vectors are introduced into host cells, allowing for temporary expression of the target gene without integration into the host cell genome. Unlike stable cell lines, the exogenous genetic material in transient systems is not maintained during cell division and is progressively diluted and lost as cells proliferate. Gene expression typically peaks between 24 and 96 hours post-transfection, followed by a gradual decline over time. The construction of transient cell lines offers several distinct advantages, including a short turnaround time, operational flexibility, and the elimination of prolonged selection processes. These features make transient systems particularly well-suited for rapid functional gene validation, small-scale protein production, and parallel screening of multiple constructs. By enabling researchers to obtain gene expression data quickly, transient cell lines serve as a critical tool in the early stages of oncology research, providing timely and reliable decision-making foundations for downstream stable cell line generation and in-depth functional studies.
Our Services
Alfa Cytology provides professional transient cell line construction services focused on achieving rapid and high-level transient expression of exogenous genes in tumor cells. Through optimized transfection protocols and expression vector design, we are able to deliver high-quality expression cell models within a short timeframe, offering flexible and efficient solutions for gene function validation, protein production, and candidate molecule screening to effectively accelerate your early-stage oncology drug discovery programs.
Service Details
| Service Step |
Service Details |
Turnaround Time |
| Construction and Preparation |
Design and construct transient expression vectors (with reporter genes or tags) based on client requirements, verify sequence accuracy by sequencing, and perform transfection-grade plasmid maxiprep.
- Vector design, synthesis, and sequence verification
- Strong promoter (CMV/EF1α) and tag selection
- Transfection-grade plasmid maxiprep
|
2–3 weeks |
| Transfection Protocol Optimization |
Screen optimal transfection conditions based on host cell type and vector characteristics.
- Liposome/PEI/electroporation method screening
- Gradient optimization of DNA/reagent ratios
- Transfection efficiency assessment (fluorescence/flow cytometry)
|
3–5 days |
| Transient Transfection |
Perform large-scale transient transfection under optimized conditions, with untransfected and empty vector controls.
- Large-scale transient transfection
- Untransfected control and empty vector control setup
|
1–2 days |
| Expression Validation |
At 24–96 hours post-transfection:
- qPCR for mRNA expression analysis
- Western blot/ELISA for protein expression analysis
- Fluorescence microscopy/flow cytometry for transfection efficiency
|
1–2 weeks |
| Scale-Up and Harvest |
Scale up the transient transfection system stepwise from 96-well plates to 6-well plates, T75 flasks, or shake flasks based on client requirements, and harvest cell lysates or culture supernatants.
- Stepwise scale-up (96→24→6-well→T75→shake flask)
- Cell lysate/culture supernatant harvest
- Protein quantification (BCA assay)
|
1–2 week |
Deliverables
- Transfected cell lysates or culture supernatants
- Untransfected control samples
- Empty vector control samples
- Transfection efficiency assessment data (if applicable)
- Gene expression validation data (qPCR, Western blot, or ELISA)
- Protein quantification data (BCA assay)
- Complete experimental report
Application
- Rapid gene function validation
- Antibody screening and antigen preparation
- Parallel screening of multiple constructs
- Signaling pathway analysis
- Protein expression condition optimization
- Gene editing efficiency assessment (CRISPR/Cas9)
- Dual-luciferase reporter assay
- RNA interference efficiency screening
- Preliminary protein-protein interaction validation
- Oncolytic target candidate screening
- Drug mechanism of action (MOA) studies
- Pre-evaluation for stable cell line development
- Small-scale recombinant protein production
Oncology Research Areas
Our transient cell line construction services cover a broad spectrum of oncology research areas, spanning major solid tumors and hematological malignancies. With extensive experience across diverse cancer types, we are well-positioned to support your specific research needs, from target validation to mechanistic studies.
Ready to accelerate your oncology research with our transient cell line construction services? Whether you need transient overexpression cell lines for rapid gene function validation or transient expression systems for small-scale protein production, Alfa Cytology is here to support you. Please don't hesitate to contact our scientific team to discuss your specific transient cell line requirements and learn how our expertise can accelerate your oncology research.
For research use only.
Related Services
